Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Patel Sanj K 2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals International, plc [KNSA] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) CHAIRMAN & CEO (Last) (First) (Middle) C/O KINIKSA PHARMACEUTICALS INT'L, 105 PICCADILLY, SECOND FLOOR 3. Date of Earliest Transaction (Month/Day/Year) 10/30/2026 (Street) LONDON W1J 7NJ 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Ordinary Share 10/30/2026 M(1) 47,530 A $8.83 999,324 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 10/30/2026 S(1) 41,169 D $92.01(2) 958,155 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 10/30/2026 S(1) 18,685 D $92.77(3) 939,470 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 10/30/2026 S(1) 15,903 D $93.62(4) 923,567 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 10/30/2026 S(1) 8,888 D $94.72(5) 914,679 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 10/30/2026 S(1) 4,490 D $95.97(6) 910,189 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 10/30/2026 S(1) 2,316 D $97.34(7) 907,373 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 10/30/2026 S(1) 1,440 D $98.16(8) 905,933 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/02/2026 M(1) 53,381 A $8.83 959,314 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/02/2026 S(1) 38,364 D $91.03(9) 920,950 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/02/2026 S(1) 24,188 D $91.83(10) 896,762 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/02/2026 S(1) 26,781 D $93.06(11) 869,981 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/02/2026 S(1) 100 D $93.97 869,881 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/03/2026 M(1) 89,089 A $8.83 958,970 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/03/2026 M(1) 41,237 A $17.92 1,000,207 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/03/2026 S(1) 1,214 D $90.77(12) 998,993 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/03/2026 S(1) 68,664 D $92.7(13) 930,329 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/03/2026 S(1) 145,708 D $93.53(14) 784,621 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 11/03/2026 S(1) 4,584 D $94.25(15) 780,037 I Held by The Anglia 2013 Revocable Trust Class A Ordinary Share 76,174 I Held by The Patel Family Irrevocable Trust of 2025 Class A Ordinary Share 109,795 I Held by The Marina 2016 Irrevocable Trust, u/d/t June 23, 2016

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Share Option

$8.83

10/30/2026

M(1)

47,530

(16)

09/16/2029

Class A Ordinary Share

47,530

$ 0

142,470

D

Share Option

$8.83

11/02/2026

M(1)

53,381

(16)

09/16/2029

Class A Ordinary Share

53,381

$ 0

89,089

D

Share Option

$8.83

11/03/2026

M(1)

89,089

(16)

09/16/2029

Class A Ordinary Share

89,089

$ 0

0

D

Share Option

$17.92

11/03/2026

M(1)

41,237

(16)

03/03/2029

Class A Ordinary Share

41,237

$ 0

145,763

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Patel Sanj K C/O KINIKSA PHARMACEUTICALS INT'L 105 PICCADILLY, SECOND FLOOR LONDON W1J 7NJ	X		CHAIRMAN & CEO

Signatures

/s/ Douglas Barry, Attorney-in-Fact		11/03/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 30, 2026.
(2)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.25 and $92.24. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(3)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.26 and $93.25. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(4)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.26 and $94.245. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(5)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.28 and $95.22. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(6)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $95.485 and $96.41. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(7)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $96.91 and $97.60. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(8)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $97.92 and $98.36. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(9)	This transaction was executed in multiple trades through a broker-dealer at prices ranging from $90.55 to $91.535. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(10)	This transaction was executed in multiple trades through a broker-dealer at prices ranging from $91.55 to $92.52. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(11)	This transaction was executed in multiple trades through a broker-dealer at prices ranging from $92.695 to $93.51. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(12)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $90.44 and $91.30. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(13)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.085 and $93.08. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(14)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.085 and $94.00. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(15)	This transaction was executed in multiple trades through a broker-dealer at prices ranging between $94.105 and $94.495. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
(16)	The option is fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.